{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088330","form_type":"8-K","ticker":null,"cik":"0001600132","company_name":"Bellerophon Therapeutics, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.500137+00:00","generated_at":"2026-06-12T04:18:48.149098+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bellerophon CEO Peter Fernandes and VP Parag Shah to depart under separation agreements","bullets":["CEO Peter Fernandes' separation effective Nov 15, 2023; receives lump sums of $205,950 plus two $102,975 payments.","VP Parag Shah's separation effective Aug 31, 2023; receives $140,600 upfront and $140,600 later.","Both will perform transition duties until separation dates and have signed release of claims and non-solicit covenants.","No successor or interim appointments announced for either departing executive."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088330","json":"https://secwatch.observer/filing/0001104659-23-088330.json","markdown":"https://secwatch.observer/filing/0001104659-23-088330.md","text":"https://secwatch.observer/filing/0001104659-23-088330.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600132/000110465923088330/0001104659-23-088330-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600132/000110465923088330/tm2322999d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:18:48.149098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"857649b369","claim":"Peter Fernandes departed as Chief Executive Officer at Bellerophon Therapeutics, Inc..","evidence_excerpt":"On August 3, 2023, Bellerophon Therapeutics, Inc. (the “Company”) entered into a transition and separation agreement with Peter Fernandes, the Company’s Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600132/000110465923088330/0001104659-23-088330-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"9f6c1b8888","claim":"Parag Shah departed as Vice President of Business Operations at Bellerophon Therapeutics, Inc..","evidence_excerpt":"and a transition and separation agreement with Parag Shah, the Company’s Vice President of Business Operations","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600132/000110465923088330/0001104659-23-088330-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Vice President of Business Operations"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}